ALIM / Alimera Sciences, Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

ALIM / Alimera Sciences, Inc. / Stonepine Capital Management, LLC Passive Investment

SC 13G/A 1 alim13ga2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 016259202 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropri

ALIM / Alimera Sciences, Inc. / BOOTHBAY FUND MANAGEMENT, LLC Passive Investment

SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 016259202 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-34703 Alimera Sciences, Inc. (Exact name of registrant as specified in

ALIM / Alimera Sciences, Inc. / Caligan Partners LP - ALIMERA SCIENCES, INC. Activist Investment

SC 13D/A 1 p24-2805sc13da.htm ALIMERA SCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 5)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Titl

As filed with the Securities and Exchange Commission on September 16, 2024

As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.

As filed with the Securities and Exchange Commission on September 16, 2024

As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.

ALIM / Alimera Sciences, Inc. / Velan Capital Investment Management LP - AMENDMENT NO. 5 TO THE SCHEDULE 13D Activist Investment

SC 13D/A 1 sc13da51292701109162024.htm AMENDMENT NO. 5 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 5)1 Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per sh

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 16, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissi

As filed with the Securities and Exchange Commission on September 16, 2024

As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.

As filed with the Securities and Exchange Commission on September 16, 2024

As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ALIMERA SCIENCES, INC.

  Exhibit 3.1   AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ALIMERA SCIENCES, INC.   FIRST:            The name of the corporation is:   ALIMERA SCIENCES, INC.   SECOND:       The address of its registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, Wilmington, Delaware, 19801, County of New Castle. The name of its registered agent at such address is T

As filed with the Securities and Exchange Commission on September 16, 2024

As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.

As filed with the Securities and Exchange Commission on September 16, 2024

As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.

As filed with the Securities and Exchange Commission on September 16, 2024

As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.

As filed with the Securities and Exchange Commission on September 16, 2024

As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.

As filed with the Securities and Exchange Commission on September 16, 2024

As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.

As filed with the Securities and Exchange Commission on September 16, 2024

As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.

As filed with the Securities and Exchange Commission on September 16, 2024

As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.

As filed with the Securities and Exchange Commission on September 16, 2024

As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.

As filed with the Securities and Exchange Commission on September 16, 2024

As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.

As filed with the Securities and Exchange Commission on September 16, 2024

As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.

As filed with the Securities and Exchange Commission on September 16, 2024

As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.

As filed with the Securities and Exchange Commission on September 16, 2024

As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.

As filed with the Securities and Exchange Commission on September 16, 2024

As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.

As filed with the Securities and Exchange Commission on September 16, 2024

As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.

As filed with the Securities and Exchange Commission on September 16, 2024

As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.

As filed with the Securities and Exchange Commission on September 16, 2024

As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.

As filed with the Securities and Exchange Commission on September 16, 2024

As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.

AMENDED AND RESTATED BY-LAWS

  Exhibit 3.2   AMENDED AND RESTATED BY-LAWS   OF   Alimera Sciences, Inc.   A Delaware Corporation   ARTICLE I   OFFICES   Section 1.      Registered Office. The registered office of the corporation in the State of Delaware shall be located at 1209 Orange Street, in the city of Wilmington, County of New Castle 19801. The name of the corporation's registered agent at such address shall be The Corp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 11, 2024 ALIMERA SCIENC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 11, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissi

ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger ANI and Alimera Scheduled the Closing for September 16, 2024

Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger ANI and Alimera Scheduled the Closing for September 16, 2024 PRINCETON, N.J. and ATLANTA, September 11, 2024 – ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI”) and Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera” or the “Company”) today jointly announced that they have scheduled the closing

Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement Alimera Has Filed Lawsuit in the Delaware Court of Chancery to Compel ANI to Close Merger Transaction and Honor its Contractual Obligations Alimera Shareholde

Exhibit 99.1 FOR IMMEDIATE RELEASE Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement Alimera Has Filed Lawsuit in the Delaware Court of Chancery to Compel ANI to Close Merger Transaction and Honor its Contractual Obligations Alimera Shareholders Approved Merger Agreement on September 4, Clearing Last Requirement for Closing ATLANTA, September 10, 2024 – Al

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 4, 2024 ALIMERA SCIENCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 4, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissio

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 10, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissi

First Amendment to Employment Agreement

Exhibit 10.3 Execution Version First Amendment to Employment Agreement This First Amendment to Employment Agreement (the “Amendment”) is entered into and effective as of September 6, 2024 (the “Effective Date”) by and between Alimera Sciences, Inc., a Delaware corporation having a principal place of business at 6310 Town Square, Suite 400, Alpharetta, Georgia (“Alimera” or the “Company”) and Jason

First Amendment to Employment Agreement

Exhibit 10.4 Execution Version First Amendment to Employment Agreement This First Amendment to Employment Agreement (the “Amendment”) is entered into and effective as of September 6, 2024 (the “Effective Date”) by and between Alimera Sciences, Inc., a Delaware corporation having a principal place of business at 6310 Town Square, Suite 400, Alpharetta, Georgia (“Alimera” or the “Company”) and Todd

First Amendment to the Amended and Restated Employment Agreement

Exhibit 10.1 Execution Version First Amendment to the Amended and Restated Employment Agreement This First Amendment to the Amended and Restated Employment Agreement (the “Amendment”) is entered into and effective as of September 6, 2024 (the “Effective Date”) by and between Alimera Sciences, Inc., a Delaware corporation having a principal place of business at 6310 Town Square, Suite 400, Alpharet

First Amendment to Employment Agreement

Exhibit 10.2 Execution Version First Amendment to Employment Agreement This First Amendment to Employment Agreement (the “Amendment”) is entered into and effective as of September 6, 2024 (the “Effective Date”) by and between Alimera Sciences, Inc., a Delaware corporation having a principal place of business at 6310 Town Square, Suite 400, Alpharetta, Georgia (“Alimera” or the “Company”) and Ellio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00

Letter Agreement, dated as of June 19, 2024, by and between Alimera Sciences, Inc. and SWK Funding LLC.

Exhibit 10.6 June 19, 2024 SWK Funding LLC c/o SWK Holdings Corporation 14755 Preston Road, Suite 105 Dallas, Texas 75254 Attention: Joe D. Staggs Re: Alternative Royalty Payment Dear Jody: This letter agreement (this “Letter Agreement”) is entered into as of the date set forth above by and between Alimera Sciences, Inc., a Delaware corporation with its principal place of business at 6310 Town Squ

Manufacturing Services Agreement, dated as of July 17, 2024, by and between Alimera Sciences, Inc. and Alliance Medical Products, Inc. d.b.a. Siegfried Irvine.

Exhibit 10.7 Portions of this document have been redacted as marked with [***] Manufacturing Services Agreement Custom Drug Product This Manufacturing Services Agreement (Agreement) is entered into as of July 17, 2024 (the Effective Date) between Alliance Medical Products, Inc., 9342 Jeronimo Rd, Irvine, CA 92618, USA (Siegfried) and Alimera Sciences, Inc., 6310 Town Square, Suite 400, Alpharetta,

 Alimera Sciences Reports Second Quarter 2024 Results

Exhibit 99.1     FOR IMMEDIATE RELEASE   Alimera Sciences Reports Second Quarter 2024 Results  ● Net Revenue up 54% to $27 Million vs. Q2 2023 ● Global End User Demand Up 6% vs. Q2 2023 ● Company Recently Announced Definitive Merger Agreement with ANI Pharmaceuticals Inc.  ATLANTA, August 6, 2024 - Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mis

 Alimera Sciences Reports Second Quarter 2024 Results

Exhibit 99.1     FOR IMMEDIATE RELEASE   Alimera Sciences Reports Second Quarter 2024 Results  ● Net Revenue up 54% to $27 Million vs. Q2 2023 ● Global End User Demand Up 6% vs. Q2 2023 ● Company Recently Announced Definitive Merger Agreement with ANI Pharmaceuticals Inc.  ATLANTA, August 6, 2024 - Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2024 ALIMERA SCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2024 ALIMERA SCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission F

CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Alimera Sciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation

Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Alimera Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 17, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction of incorporation) (Commission Fi

Voting Agreement

Exhibit 10.1 Execution Version ** Certain terms of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K as they are both not material and of the type that the registrant treats as private or confidential. The registrant agrees to supplementally furnish an unredacted copy of this exhibit to the SEC upon its request; however, the registrant may request confidential treatm

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 21, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 21, 2024 ALIMERA SCIENCES, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 21, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction of incorporation) (Commission Fi

ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences Conference call scheduled for today at 8:30 a.m. ET

Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences Conference call scheduled for today at 8:30 a.m. ET · Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenue · Adds two commercial assets ILUVIEN® and YUTIQ® with significant

ALIM / Alimera Sciences, Inc. / Caligan Partners LP - ALIMERA SCIENCES, INC. Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 4)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) Da

Agreement and Plan of Merger

Exhibit 2.1 EXECUTION VERSION CONFIDENTIAL AGREEMENT AND PLAN OF MERGER BY AND AMONG: ANI PHARMACEUTICALS, INC. ANIP MERGER SUB INC. and ALIMERA SCIENCES, INC. DATED AS OF JUNE 21, 2024 * The disclosure schedules to and certain provisions of this exhibit have been omitted pursuant to Item 601(b)(2)(ii) of Regulation S-K as they contain information that is both not material and of the type that the

ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences Conference call scheduled for today at 8:30 a.m. ET

Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences Conference call scheduled for today at 8:30 a.m. ET · Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenue · Adds two commercial assets ILUVIEN® and YUTIQ® with significant

Voting Agreement

Exhibit 10.1 Execution Version ** Certain terms of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K as they are both not material and of the type that the registrant treats as private or confidential. The registrant agrees to supplementally furnish an unredacted copy of this exhibit to the SEC upon its request; however, the registrant may request confidential treatm

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 19, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction of incorporation) (Commission Fi

Agreement and Plan of Merger

Exhibit 2.1 EXECUTION VERSION CONFIDENTIAL AGREEMENT AND PLAN OF MERGER BY AND AMONG: ANI PHARMACEUTICALS, INC. ANIP MERGER SUB INC. and ALIMERA SCIENCES, INC. DATED AS OF JUNE 21, 2024 * The disclosure schedules to and certain provisions of this exhibit have been omitted pursuant to Item 601(b)(2)(ii) of Regulation S-K as they contain information that is both not material and of the type that the

ALIM / Alimera Sciences, Inc. / Velan Capital Investment Management LP - AMENDMENT NO. 4 TO THE SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) Adam Morgan Vel

Seventh Amendment to Loan and Security Agreement dated as of March 6, 2024, by and among Alimera Sciences, Inc., SLR Investment Corp., as Collateral Agent, and the parties signatory thereto as Lenders, including SLR in its capacity as a Lender

Exhibit 10.4 Execution Version  CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.  SEVENTH AMENDMENT TO LOAN AND SECURITY AGREEMENT  THIS SEVENTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of March 6, 2024 (the “Seventh Amendment Effective Da

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT P

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission Fil

 Alimera Sciences Reports First Quarter 2024 Results

Exhibit 99.1     FOR IMMEDIATE RELEASE   Alimera Sciences Reports First Quarter 2024 Results  · Net Revenue up 70% to $23 Million vs. Q1 2023 · Global End User Demand Up 23% vs. Q1 2023 · Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance  ATLANTA, May 14, 2024 - Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invalua

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One)  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-

Filing Fee Table

Exhibit 107  Calculation of Filing Fee Tables  FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933  ALIMERA SCIENCES, INC.

List of subsidiaries of the Registrant (including jurisdiction of organization and names under which subsidiaries do business)

Exhibit 21.1 Alimera Sciences, Inc. List of Subsidiaries   Name of Wholly-Owned Subsidiary Jurisdiction of Organization Name under which the subsidiary conducts business Alimera Sciences Limited United Kingdom Alimera Sciences Limited Alimera Sciences Opthamologie GmbH Germany Alimera Sciences Opthamologie GmbH Alimera Sciences Europe Limited Ireland Alimera Sciences Europe Limited 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34

As filed with the Securities and Exchange Commission on March 8, 2024

As filed with the Securities and Exchange Commission on March 8, 2024 Registration No.

Alimera Sciences, Inc. Clawback Policy ‎

Exhibit 97.1  ALIMERA SCIENCES, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED INCENTIVE COMPENSATION  (Adopted: November 21, 2023) 1. INTRODUCTION Alimera Sciences, Inc. (the “Company”) is adopting this policy (this “Policy”) to provide for the Company’s recovery of certain Incentive Compensation (as defined below) erroneously awarded to Affected Officers (as defined below) under certain circu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 6, 2024 ALIMERA SCIENCES, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 6, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission Fi

Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results Q4 Net Revenues up 88% to $26.3 million vs. Q4 2022 2023 Net Revenues up 49% to $80.8 million vs. 2022 Increases 2024 Revenue Guidance

Exhibit 99.1  FOR IMMEDIATE RELEASE  Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results  Q4 Net Revenues up 88% to $26.3 million vs. Q4 2022 2023 Net Revenues up 49% to $80.8 million vs. 2022 Increases 2024 Revenue Guidance   ATLANTA, March 7, 2024 - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients,

ALIM / Alimera Sciences, Inc. / LYTTON LAURENCE W Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r

ALIM / Alimera Sciences, Inc. / HBM Healthcare Investments (Cayman) Ltd. - SC 13G/A Passive Investment

SC 13G/A 1 tm245871d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Che

Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

EX-1 2 ex-1.htm JOINT ACQUISITION STATEMENT Page 9 of 9 Altium Capital Management, LP SC 13G/A EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of

ALIM / Alimera Sciences, Inc. / Stonepine Capital Management, LLC Passive Investment

SC 13G/A 1 alim13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 016259202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriat

ALIM / Alimera Sciences, Inc. / Altium Capital Management LP - AMENDMENT TO FORM SC 13G Passive Investment

SC 13G/A 1 altium-sc13ga.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Alimera Sciences, Inc (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 016259202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this

ALIM / Alimera Sciences, Inc. / BOOTHBAY FUND MANAGEMENT, LLC Passive Investment

SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 016259202 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to

As filed with the Securities and Exchange Commission on February 9, 2024

As filed with the Securities and Exchange Commission on February 9, 2024 Registration No.

Form of Performance Stock Unit Agreement under the 2024 Equity Inducement Plan

Exhibit 10.3 Alimera Sciences, Inc. 2024 Equity Inducement Plan  Notice of Performance Stock Unit Award Pursuant to the Alimera Sciences, Inc. 2024 Equity Inducement Plan (the “Inducement Plan”), Alimera Sciences, Inc. (the “Company”) hereby grants you the following Performance Stock Units (“PSUs”), each representing the right to receive one share of the Company’s common stock (a “Common Share”),

As filed with the Securities and Exchange Commission on February 9, 2024

As filed with the Securities and Exchange Commission on February 9, 2024 Registration No.

Form of Stock Option Agreement under the 2024 Equity Inducement Plan

Exhibit 10.2 Alimera Sciences, Inc. 2024 Equity Inducement Plan  Notice of Stock Option Award Pursuant to the Alimera Sciences, Inc. 2024 Equity Inducement Plan (the “Inducement Plan”), Alimera Sciences, Inc. (the “Company”) hereby grants you the following option (the “Option”) to purchase shares of the Company’s common stock (the “Common Shares”), subject to the terms and conditions set forth in

Alimera Sciences, Inc. 2024 Equity Inducement Plan as Adopted on February 8, 2024 (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, as filed February 9, 2024, and incorporated herein by reference)

Exhibit 10.1 Alimera Sciences, Inc. 2024 Equity Inducement Plan (As Adopted on February 8, 2024)  Alimera Sciences, Inc. 2024 Equity Inducement Plan PURPOSE . The purpose of the Plan is to attract, retain, and motivate highly-qualified prospective officers and employees for positions of substantial responsibility by providing an inducement material to their entering into employment with the Compa

Filing Fee Table.

Exhibit 107  Calculation of Filing Fee Tables  FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933  ALIMERA SCIENCES, INC.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES ‎SECURITIES AND EXCHANGE COMMISSION ‎Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ‎SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction ‎of incorporation) (Commis

Form of Restricted Stock Unit Agreement under the 2024 Equity Inducement Plan

Exhibit 10.4 Alimera Sciences, Inc. 2024 Equity Inducement Plan  Notice of Restricted Stock Unit Award Pursuant to the Alimera Sciences, Inc. 2024 Equity Inducement Plan (the “Inducement Plan”), Alimera Sciences, Inc. (the “Company”) hereby grants you the following Restricted Stock Units (“RSUs”), each representing the right to receive one share of the Company’s common stock (a “Common Share”), s

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables  FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933  ALIMERA SCIENCES, INC.

Separation Agreement and General Release, dated January 2, 2024, by and between Alimera Sciences, Inc. and Russell Skibsted

EXHIBIT 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE This SEPARATION AGREEMENT AND GENERAL RELEASE (“Agreement”) is entered into by and between Russell L. Skibsted (“Executive”), for himself and his heirs, executors, administrators, successors, and assigns, and Alimera Sciences, Inc. (“Company”) (Executive and Company each a “Party,” and together, the “Parties”). In consideration of the promises

Employment Agreement, dated as of (filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, as filed on January 4, 2024, and incorporated herein by reference)

EXHIBIT 10.2 EMPLOYMENT AGREEMENT WITH ALIMERA SCIENCES, INC. This Employment Agreement (this “Agreement”) is entered into between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and Elliot Maltz (“Executive”), as of January 2, 2024. RECITALS: WHEREAS, the Company is engaged in the business of developing, marketing and selling ophthalmic pharmaceuticals in the United States and thr

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 28, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction of incorporation) (Commissio

Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Exhibit 99.1 Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ATLANTA, January 2, 2024 - Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better visio

Inducement Stock Option Agreement, dated as of January 2, 2024, by and between Alimera Sciences, Inc. and Elliot Maltz (Non-Plan Inducement Award)

EXHIBIT 10.3 ALIMERA SCIENCES, INC. Inducement Stock Option Agreement (Non-Plan Inducement Award) Pursuant to your employment agreement with Alimera Sciences, Inc. (the “Company”), dated December 11, 2023 (the “Employment Agreement”), the Company hereby grants to you (“Executive” or “you”) the following inducement option (the “Option”) to purchase shares of the Company’s common stock (the “Common

Employment Agreement, dated as of December 11, 2023, by and between Alimera Sciences, Inc. and Todd Wood

Exhibit 10.2 EMPLOYMENT AGREEMENT WITH ALIMERA SCIENCES, INC. This Employment Agreement (this “Agreement”) is entered into between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and Todd Wood (“Executive”), as of December 11, 2023. RECITALS: WHEREAS, the Company is engaged in the business of developing, marketing and selling ophthalmic pharmaceuticals in the United States and thro

Amended and Restated Employment Agreement, dated as of December 11, 2023, by and between Alimera Sciences, Inc. and Richard S. Eiswirth, Jr.

Exhibit 10.1  AMENDED AND RESTATED EMPLOYMENT AGREEMENT WITH ALIMERA SCIENCES, INC. This Amended and Restated Employment Agreement (this “Agreement”) is entered into between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and Richard S. Eiswirth, Jr. (“Executive”), as of December 11, 2023 (the “Effective Date”). RECITALS: WHEREAS, the Company is engaged in the business of developi

Inducement Stock Option Agreement, dated as of December 11, 2023, by and between Alimera Sciences, Inc. and Todd Wood (Non-Plan Inducement Award)

Exhibit 10.3 ALIMERA SCIENCES, INC. Inducement Stock Option Agreement (Non-Plan Inducement Award)  Pursuant to your employment agreement with Alimera Sciences, Inc. (the “Company”), dated December 11, 2023 (the “Employment Agreement”), the Company hereby grants to you (“Executive” or “you”) the following inducement option (the “Option”) to purchase shares of the Company’s common stock (the “Commo

 Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Exhibit 99.1   Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)  ATLANTA, December 12, 2023 - Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining

UNITED STATES ‎SECURITIES AND EXCHANGE COMMISSION ‎Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ‎SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 11, 2023 ALIMERA SCIE

UNITED STATES ‎SECURITIES AND EXCHANGE COMMISSION ‎Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ‎SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 11, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction ‎of incorporation) (Commi

 Alimera Appoints Maggie A. Pax to Its Board of Directors

 FOR IMMEDIATE RELEASE  Alimera Appoints Maggie A. Pax to Its Board of Directors  ATLANTA (November 8, 2023) – Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Maggie A. Pax to its Board of Di

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 o TRANSITION REPO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 26, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission

Alimera Sciences Reports Third Quarter 2023 Results

 FOR IMMEDIATE RELEASE Alimera Sciences Reports Third Quarter 2023 Results  · Net Revenue up 72% to $23.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 ALIMERA SCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction of incorporation) (Commission

Employment Agreement dated as of October 2, 2023 between Alimera Sciences, Inc. and Jason Werner

Exhibit 10.1  EMPLOYMENT AGREEMENT WITH ALIMERA SCIENCES, INC. This Employment Agreement (this “Agreement”) is entered into between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and Jason Werner (“Executive”), as of October 2, 2023. RECITALS: WHEREAS, the Company is engaged in the business of developing, marketing and selling ophthalmic pharmaceuticals in the United States and t

 Alimera Sciences Appoints Jason Werner as Chief Operating Officer Dr. Philip Ashman Appointed as President of International Operations

Exhibit 99.1   Alimera Sciences Appoints Jason Werner as Chief Operating Officer  Dr. Philip Ashman Appointed as President of International Operations   ATLANTA, October 3, 2023 - Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision

Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

Altium Capital Management, LP SC 13G Page 9 of 9 EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.

ALIM / Alimera Sciences Inc. / Altium Capital Management LP - SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP Passive Investment

SC 13G 1 alimsc13g-082223.htm SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Alimera Sciences, Inc (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 016259202 (CUSIP Number) August 15, 2023 (Date of Even

ALIM / Alimera Sciences Inc. / Velan Capital Investment Management LP - AMENDMENT NO. 3 TO THE SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) Adam Morgan Vel

Certificate of Elimination of Series B Convertible Preferred Stock (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, as filed on August 15, 2023, and incorporated herein by reference).

Exhibit 3.1 CERTIFICATE OF ELIMINATION OF SERIES B CONVERTIBLE PREFERRED STOCK, PAR VALUE $0.01 PER SHARE, OF ALIMERA SCIENCES, INC.  Pursuant to Section 151(g) of the Delaware General Corporation Law  Alimera Sciences, Inc. (the “Company”), a corporation organized and existing under the laws of the State of Delaware, certifies as follows:  FIRST: By a Certificate of Designation filed with the

Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 15, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission

ALIM / Alimera Sciences Inc. / LYTTON LAURENCE W Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) August 2, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

Omnibus Exit Fee Agreement dated as of May 17, 2023, by and among Alimera Sciences, Inc., SLR Investment Corp., as Collateral Agent, and the parties signatory thereto as Lenders, including SLR in its capacity as a Lender

Exhibit 10.4  OMNIBUS AMENDMENT TO EXIT FEE AGREEMENTS THIS OMNIBUS AMENDMENT TO EXIT FEE AGREEMENTS (this “Amendment”), dated as of May 18, 2023 (the “Sixth Amendment Effective Date”), is made by and among Alimera Sciences, Inc., a Delaware corporation (the “Borrower”), SLR Investment Corp. (formerly known as Solar Capital Ltd.) (“Solar”), in its capacity as collateral agent (together with its s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 o TRANSITION REPORT PU

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00

As filed with the Securities and Exchange Commission on August 11, 2023

As filed with the Securities and Exchange Commission on August 11, 2023 Registration No.

Sixth Amendment to Loan and Security Agreement dated as of May 17, 2023, by and among Alimera Sciences, Inc., SLR Investment Corp., as Collateral Agent, and the parties signatory thereto as Lenders, including SLR in its capacity as a Lender.***

Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS (I) NOT MATERIAL AND (II) OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of May 17, 2023 (the “Sixth Amendment Effective Date”), b

Joinder and Amendment to Registration Rights Agreement dated as of May 17, 2023, by and among Alimera Sciences, Inc. and the purchasers party thereto.

Exhibit 10.5  JOINDER AND AMENDMENT TO REGISTRATION RIGHTS AGREEMENT  This Joinder and Amendment to Registration Rights Agreement (this “Amendment”) dated as of May 17, 2023 (the “Amendment Effective Date”), between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto, amends that certain Registration Rights Agreement (the “R

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables  FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933  ALIMERA SCIENCES, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 ALIMERA SCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission

ALIM / Alimera Sciences Inc. / BOOTHBAY FUND MANAGEMENT, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Alimera Sciences, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 016259202 (CUSIP Number) August 1, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched

ALIM / Alimera Sciences Inc. / Stonepine Capital Management, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Alimera Sciences, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 016259202 (CUSIP Number) August 2, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

Alimera Sciences Reports Second Quarter 2023 Results

 FOR IMMEDIATE RELEASE Alimera Sciences Reports Second Quarter 2023 Results  · Alimera Acquired U.

ALIM / Alimera Sciences Inc. / Caligan Partners LP - ALIMERA SCIENCES, INC. Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) Da

ALIM / Alimera Sciences Inc. / Velan Capital Investment Management LP - AMENDMENT NO. 2 TO THE SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) Adam Morgan Vel

Alimera Sciences, Inc. 2023 Equity Incentive Plan and forms of award agreements thereunder (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, as filed on August 2, 2023, and incorporated herein by reference).

EXHIBIT 10.1  Alimera Sciences, Inc. 2023 Equity Incentive Plan (As Adopted on June 15, 2023) Alimera Sciences, Inc. 2023 Equity Incentive Plan ARTICLE 1. INTRODUCTION. The Plan was adopted by the Board on June 15, 2023, and will become effective immediately upon its approval by the Company’s stockholders. The purpose of the Plan is to promote the long-term success of the Company and the creation

Chairman Emeritus Agreement, dated as of August 1, 2023 by and between Alimera Sciences, Inc. and C. Daniel Myers (filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, as filed on August 2, 2023, and incorporated herein by reference).

Exhibit 10.2  CHAIRMAN EMERITUS AGREEMENT  This Chairman Emeritus Agreement (this “Agreement”) is entered into by and between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and C. Daniel Myers (“Myers”), as of August 1, 2023.  RECITALS:  WHEREAS, the Company is engaged in the business of developing, marketing and selling ophthalmic pharmaceuticals in the United States and thro

Certificate of Amendment to Certificate of Designation of Series B Convertible Preferred Stock (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, as filed on August 2, 2023, and incorporated herein by reference).

Exhibit 3.1 ALIMERA SCIENCES, INC. CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF DESIGNATION OF SERIES b CONVERTIBLE PREFERRED STOCK  (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Pursuant to Section 242 of the General Corporation Law of the State of Delaware (the “DGCL”), Alimera Sciences, Inc. (the “Corporation”), a corporation organized and existing under t

Form of Pre-Funded Warrant (filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, as filed on August 2, 2023, and incorporated herein by reference).

Exhibit 4.1 THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAI

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission F

ALIMERA SCIENCES, INC. PROSPECTUS SUPPLEMENT NO. 1 TO PROSPECTUS DATED July 12, 2023

Filed Pursuant to Rule 424(b)(3) Registration No. 333-273090 ALIMERA SCIENCES, INC. PROSPECTUS SUPPLEMENT NO. 1 TO PROSPECTUS DATED July 12, 2023 This Prospectus Supplement No. 1 supplements and amends the prospectus dated July 12, 2023 (the “Prospectus”), covering the offering and sale of up to 49,763,960 shares of common stock, par value $0.01 per share (the “Common Stock”), of Alimera Sciences,

ALIMERA SCIENCES, INC. Up to 49,763,960 Shares of Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-273090 PROSPECTUS  ALIMERA SCIENCES, INC. Up to 49,763,960 Shares of Common Stock   This prospectus relates to the resale or other disposition from time to time of up to 49,763,960 shares of common stock, par value $0.01 per share (the “Common Stock”), of Alimera Sciences, Inc., a Delaware corporation, consisting of (i) 45,617,114 shares of

Alimera Sciences, Inc. 6310 Town Square, Suite 400 Alpharetta, GA 30005

Alimera Sciences, Inc. 6310 Town Square, Suite 400 Alpharetta, GA 30005 July 10, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attn: Cindy Polynice Re: Alimera Sciences, Inc. Registration Statement on Form S-3 (File No. 333-273090) Ladies and Gentlemen: Pursuant to Rules 460 and 461 under the Securities Act of 1933, as am

As filed with the Securities and Exchange Commission on June 30, 2023

As filed with the Securities and Exchange Commission on June 30, 2023 Registration No.

Filing Fee Table (filed herewith)

Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) ALIMERA SCIENCES, INC.

UNITED STATES

UNITED STATES  SECURITIES AND EXCHANGE COMMISSION  Washington, D.C. 20549  SCHEDULE 14A  Proxy Statement Pursuant to Section 14(a) of the  Securities Exchange Act of 1934    Filed by the Registrant ☒Filed by a Party other than the Registrant ☐   Check the appropriate box:  ¨ Preliminary Proxy Statement  ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 28, 2023 ALIMERA SCIENCES, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 28, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission Fi

UNITED STATES

UNITED STATES  SECURITIES AND EXCHANGE COMMISSION  Washington, D.C. 20549  SCHEDULE 14A  Proxy Statement Pursuant to Section 14(a) of the  Securities Exchange Act of 1934   Filed by the Registrant ☒Filed by a Party other than the Registrant ☐   Check the appropriate box:  x Preliminary Proxy Statement  ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 7, 2023 ALIMERA SCIENCES, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 7, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission Fil

JOINT FILING AGREEMENT

Exhibit 99.4 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the common stock, par value $0.01 per share, of Alimera Sciences, Inc., a Delaware corporation. This Jo

ALIM / Alimera Sciences Inc. / Velan Capital Investment Management LP - AMENDMENT NO. 1 TO THE SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) Adam Morgan Vel

May 17, 2023

Exhibit 99.3 May 17, 2023 Alimera Sciences, Inc. Re: Support Agreement Dear Ladies and Gentlemen: The undersigned understands that Alimera Sciences, Inc., a Delaware corporation (“Company”), and certain investors, including the undersigned (the “Investors”), are entering into a Joinder and Amendment to Securities Purchase Agreement dated as of the date hereof (the “Amendment”), which amends that c

Commercial Supply Agreement, dated May 17, 2023, by and Alimera Sciences, Inc. and EyePoint Pharmaceuticals, Inc.

Exhibit 10.1 EXECUTION COPY Confidential CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS (I) NOT MATERIAL AND (II) OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COMMERCIAL SUPPLY AGREEMENT This COMMERCIAL SUPPLY AGREEMENT (this “Agreement”) is made as of May 17, 2023 (the “Effective Date”), by and between EyePoint Ph

Joinder and Amendment to Securities Purchase Agreement, dated May 17, 2023, by and among Alimera Sciences, Inc. and the purchasers party thereto

Exhibit 10.2 Execution Version JOINDER AND AMENDMENT TO SECURITIES PURCHASE AGREEMENT  This Joinder and Amendment to Securities Purchase Agreement (this “Amendment”) dated as of May 17, 2023 (the “Amendment Effective Date”), between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto, amends that certain Securities Purchase A

Certificate of Amendment to Certificate of Designation of Series B Convertible Preferred Stock (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, as filed on May 18, 2023, and incorporated herein by reference).

Exhibit 3.1 ALIMERA SCIENCES, INC. CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF DESIGNATION OF SERIES b CONVERTIBLE PREFERRED STOCK  (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Pursuant to Section 242 of the General Corporation Law of the State of Delaware (the “DGCL”), Alimera Sciences, Inc. (the “Corporation”), a corporation organized and existing under t

Product Rights Agreement, dated May 17, 2023, by and Alimera Sciences, Inc. and EyePoint Pharmaceuticals, Inc.

Exhibit 2.1   CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.   PRODUCT RIGHTS AGREEMENT between EyePoint Pharmaceuticals, Inc. and Alimera Sciences, Inc.  May 17, 2023  TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS.....................

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction of incorporation) (Commission Fil

Alimera Acquires U.S. Commercial Rights to YUTIQ®

Exhibit 99.1   FOR IMMEDIATE RELEASE  Alimera Acquires U.S. Commercial Rights to YUTIQ®  · Expected to be immediately accretive to revenue and Adjusted EBITDA in 2023 · Alimera projects at least $100 million of consolidated net revenue and over $20 million of Adjusted EBITDA* in 2024 · Leverages Alimera’s existing U.S. commercial infrastructure · Industry veteran Jason Werner added to Alimera

ALIM / Alimera Sciences Inc. / Caligan Partners LP - ALIMERA SCIENCES, INC. Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) Da

Fifth Amendment Exit Fee Agreement dated as of March 24, 2023, by and among Alimera Sciences, Inc., SLR Investment Corp, as Collateral Agent, and the parties signatory thereto as Lenders, including SLR in its capacity as a Lender

Exhibit 10.4  Fifth Amendment Exit Fee Agreement  Reference is made to the Loan and Security Agreement, dated as of December 31, 2019 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Loan Agreement”) by and among SLR Investment Corp., a Maryland corporation (formerly known as Solar Capital Ltd.) (“Solar”), as collateral agent (in such capacity, “Agent

Fifth Amendment to Loan and Security Agreement dated as of March 24, 2023, by and among Alimera Sciences, Inc., SLR Investment Corp, as Collateral Agent, and the parties signatory thereto as Lenders, including SLR in its capacity as a Lender***

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS (I) NOT MATERIAL AND (II) OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

 Alimera Sciences Reports First Quarter 2023 Results

Exhibit 99.1  FOR IMMEDIATE RELEASE   Alimera Sciences Reports First Quarter 2023 Results  · Consolidated Net Revenue of $13.5 Million Up 14% vs. First Quarter of 2022 · Global End User Demand Up 14% vs. First Quarter of 2022 · Financial Results and Corporate Update Conference Call Cancelled   ATLANTA, May 15, 2023 - Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 o TRANSITION REPORT P

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One)  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-

As filed with the Securities and Exchange Commission on April 28, 2023

As filed with the Securities and Exchange Commission on April 28, 2023 Registration No.

Filing Fee Table

Exhibit 107.1 Calculation of Filing Fee Tables  FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933  ALIMERA SCIENCES, INC. (Exact Name of Registrant as Specified in its Charter)  Table 1: Newly Registered Securities    Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate A

ALIM / Alimera Sciences Inc. / Palo Alto Investors LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 15) Alimera Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 016259202 (CUSIP Number) March 24, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch

List of subsidiaries of the Registrant (including jurisdiction of organization and names under which subsidiaries do business)

Exhibit 21.1 Alimera Sciences, Inc. List of Subsidiaries   Name of Wholly-Owned Subsidiary Jurisdiction of Organization Name under which the subsidiary conducts business Alimera Sciences Limited United Kingdom Alimera Sciences Limited Alimera Sciences Opthamologie GmbH Germany Alimera Sciences Opthamologie GmbH Alimera Sciences Europe Limited Ireland Alimera Sciences Europe Limited 

ALIM / Alimera Sciences Inc. / Velan Capital Investment Management LP - SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) Adam Morgan Vela

Alimera Sciences Announces 2022 Financial Results and Business Update

Exhibit 99.1  FOR IMMEDIATE RELEASE  Alimera Sciences Announces 2022 Financial Results and Business Update · 2022 Product Revenue Increased to $54.1 Million, Up 13% over 2021 · Global End User Demand Increased 22% over 2021 to 9,266 Units · Strengthened Balance Sheet, Repurchased Stock and Extended Term Loan Facility   ATLANTA, March 31, 2023 - Alimera Sciences, Inc. (Nasdaq: ALIM) a global ph

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 ALIMERA SCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34

Fourth Amendment to Loan and Security Agreement dated as of December 7, 2022, by and among Alimera Sciences, Inc., SLR Investment Corp, as Collateral Agent, and the parties signatory thereto as Lenders, including SLR in its capacity as a Lender

Certain information in this document has been omitted pursuant to Regulation S-K, Item 601(b)(10).

JOINT FILING AGREEMENT

Exhibit 99.5 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the common stock, par value $0.01 per share, of Alimera Sciences, Inc., a Delaware corporation. This Jo

ALIM / Alimera Sciences Inc. / Caligan Partners LP - ALIMERA SCIENCES, INC. Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) Da

Certificate of Designation of Series B Convertible Preferred Stock

EX-3.1 2 alim-20230323xex31.htm EX-3.1 Exhibit 3.1 ALIMERA SCIENCES, INC. CERTIFICATE OF DESIGNATION OF SERIES b CONVERTIBLE PREFERRED STOCK (Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware) Pursuant to Section 151 of the General Corporation Law of the State of Delaware (the “DGCL”), Alimera Sciences, Inc. (the “Corporation”), a corporation organized and existing

Securities Purchase Agreement, dated March 24, 2023, by and among Alimera Sciences, Inc. and the purchasers party thereto

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (as may be amended or restated, this “Agreement”) is dated as of March 24, 2023, between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser”, and collectively, the “Purchasers”). WHEREAS, sub

Form of Warrant to Purchase Shares of Common Stock

EX-4.1 5 alim-20230323xex41.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD

Form of Warrant to Purchase Shares of Common Stock

EX-4.1 5 alim-20230323xex41.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD

Certificate of Elimination of Series C Convertible Preferred Stock (filed as Exhibit 3.3 to the Registrant’s Form 8-K, as filed March 27, 2023, and incorporated herein by reference)

Exhibit 3.3 CERTIFICATE OF ELIMINATION OF SERIES C CONVERTIBLE PREFERRED STOCK, PAR VALUE $0.01 PER SHARE, OF ALIMERA SCIENCES, INC.  Pursuant to Section 151(g) of the Delaware General Corporation Law  Alimera Sciences, Inc. (the “Company”), a corporation organized and existing under the laws of the State of Delaware, certifies as follows:  FIRST: By a Certificate of Designation filed with the

Securities Purchase Agreement, dated March 24, 2023, by and among Alimera Sciences, Inc. and the purchasers party thereto

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (as may be amended or restated, this “Agreement”) is dated as of March 24, 2023, between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser”, and collectively, the “Purchasers”). WHEREAS, sub

Certificate of Elimination of Series A Convertible Preferred Stock

Exhibit 3.2 CERTIFICATE OF ELIMINATION OF SERIES A CONVERTIBLE PREFERRED STOCK, PAR VALUE $0.01 PER SHARE, OF ALIMERA SCIENCES, INC.  Pursuant to Section 151(g) of the Delaware General Corporation Law  Alimera Sciences, Inc. (the “Company”), a corporation organized and existing under the laws of the State of Delaware, certifies as follows:  FIRST: By a Certificate of Designation filed with the

Press Release of Alimera Sciences, Inc. dated March 27, 2023

Exhibit 99.1  FOR IMMEDIATE RELEASE   Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility  · Repurchases Series A Preferred Stock, eliminating $24 million liquidation preference for approximately $938,000 · Completes $12 million private placement of preferred stock and warrants with conversion price and exercise price at 55% premium to the closing share

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 23, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission F

Certificate of Designation of Series B Convertible Preferred Stock (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, as filed on March 27, 2023, and incorporated herein by reference).

EX-3.1 2 alim-20230323xex31.htm EX-3.1 Exhibit 3.1 ALIMERA SCIENCES, INC. CERTIFICATE OF DESIGNATION OF SERIES b CONVERTIBLE PREFERRED STOCK (Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware) Pursuant to Section 151 of the General Corporation Law of the State of Delaware (the “DGCL”), Alimera Sciences, Inc. (the “Corporation”), a corporation organized and existing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 23, 2023 ALIMERA SCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549  FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934  Date of Report (Date of earliest event reported): March 23, 2023  ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter)    Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (

 Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility

EX-99.1 8 alim-20230323xex991.htm EX-99.1 Exhibit 99.1  FOR IMMEDIATE RELEASE   Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility  · Repurchases Series A Preferred Stock, eliminating $24 million liquidation preference for approximately $938,000 · Completes $12 million private placement of preferred stock and warrants with conversion price and exercise

Registration Rights Agreement, dated March 2023, by and among Alimera Sciences, Inc. and the purchasers party thereto (filed as Exhibit 10.2 to the Registrant’s Form 8-K, as filed on March 27, 2023, and incorporated herein by reference)

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT  THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of March 24, 2023, by and among Alimera Sciences, Inc., a Delaware corporation (the “Company”), and the purchasers set forth on Schedule 1 hereto (each, a “Purchaser”, and collectively, the “Purchasers”), and shall become effective as of the Closing Date (as defined below)

Certificate of Elimination of Series A Convertible Preferred Stock (filed as Exhibit 3.2 to the Registrant’s Form 8-K, as filed March 27, 2023, and incorporated herein by reference)

Exhibit 3.2 CERTIFICATE OF ELIMINATION OF SERIES A CONVERTIBLE PREFERRED STOCK, PAR VALUE $0.01 PER SHARE, OF ALIMERA SCIENCES, INC.  Pursuant to Section 151(g) of the Delaware General Corporation Law  Alimera Sciences, Inc. (the “Company”), a corporation organized and existing under the laws of the State of Delaware, certifies as follows:  FIRST: By a Certificate of Designation filed with the

Registration Rights Agreement, dated March 24, 2023, by and among Alimera Sciences, Inc. and the purchasers party thereto

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT  THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of March 24, 2023, by and among Alimera Sciences, Inc., a Delaware corporation (the “Company”), and the purchasers set forth on Schedule 1 hereto (each, a “Purchaser”, and collectively, the “Purchasers”), and shall become effective as of the Closing Date (as defined below)

Certificate of Elimination of Series C Convertible Preferred Stock

Exhibit 3.3 CERTIFICATE OF ELIMINATION OF SERIES C CONVERTIBLE PREFERRED STOCK, PAR VALUE $0.01 PER SHARE, OF ALIMERA SCIENCES, INC.  Pursuant to Section 151(g) of the Delaware General Corporation Law  Alimera Sciences, Inc. (the “Company”), a corporation organized and existing under the laws of the State of Delaware, certifies as follows:  FIRST: By a Certificate of Designation filed with the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2023 ALIMERA SCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2023 ALIMERA SCIENCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissio

Alimera Appoints Roger Sawhney, M.D. to Its Board of Directors

Exhibit 99.1  FOR IMMEDIATE RELEASE  Alimera Appoints Roger Sawhney, M.D. to Its Board of Directors  ATLANTA (February 27, 2023) – Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Roger Sawhne

 Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer

EX-99.1 3 alim-20230106xex991.htm EX-99.1 Exhibit 99.1   FOR IMMEDIATE RELEASE   Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer   ATLANTA, January 9, 2022 - Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maint

Employment Agreement, dated as of January 9, 2023, by and between Alimera Sciences, Inc. and Russell L. Skibsted (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, as filed January 10, 2023, and incorporated herein by reference)

Exhibit 10.1 EMPLOYMENT AGREEMENT WITH ALIMERA SCIENCES, INC.   This Employment Agreement (this “Agreement”) is entered into between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and Russell L. Skibsted (“Executive”), as of January 9, 2022 (the “Effective Date”).  RECITALS:  WHEREAS, the Company is engaged in the business of developing, marketing and selling ophthalmic pharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 6, 2023 ALIMERA SCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 6, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 7, 2022 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission

Alimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan Agreement

Exhibit 99.1 ? FOR IMMEDIATE RELEASE ? Alimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan Agreement ? ? ATLANTA, December 8, 2022 - Alimera Sciences, Inc. (Nasdaq: ALIM) (?Alimera?), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 o TRANSITION REPO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe

Alimera Sciences Announces Third Quarter 2022 Financial Results

Exhibit 99.1  FOR IMMEDIATE RELEASE  Alimera Sciences Announces Third Quarter 2022 Financial Results  · Consolidated Net Product Revenue of $13.6 Million, up 11% vs. Third Quarter of 2021 o Net Product Revenue Was Unfavorably Impacted by Approximately $800,000 in Foreign Currency Fluctuations · Excluding Fluctuations in Foreign Currency Exchange Rates, Consolidated Net Product Revenue Would Hav

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 10, 2022 ALIMERA SCIENCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 10, 2022 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissio

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2022 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 o TRANSITION REPORT PU

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00

Alimera Sciences Announces Second Quarter 2022 Financial Results

Exhibit 99.1 ? FOR IMMEDIATE RELEASE ? Alimera Sciences Announces Second Quarter 2022 Financial Results ? ? Consolidated Net Product Revenue of $14.6 Million up 36% vs. Second Quarter of 2021 ? U.S. End User Demand up 45% vs. Second Quarter of 2021 ? International Segment End User Demand Up 21% vs. Second Quarter of 2021 ? ? ATLANTA, July 27, 2022 - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera),

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 27, 2022 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission Fi

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 12, 2022 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission Fi

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 7, 2022 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission Fil

Corporate Presentation

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definitive Proxy

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definitive Proxy

ALIM / Alimera Sciences Inc / Caligan Partners LP - ALIMERA SCIENCES, INC. Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. )* Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) David

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 o TRANSITION REPORT P

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0

Third Amendment to Loan and Security Agreement dated as of February 22, 2022, by and among Alimera Sciences, Inc., SLR Investment Corp, as Collateral Agent, and the parties signatory thereto as Lenders, including SLR in its capacity as a Lender (filed as Exhibit 10.11.G to the Registrant’s Quarterly Report on Form 10-Q, as filed May 12, 2022, and incorporated herein by reference)

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2022 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission File

Alimera Sciences Reports First Quarter 2022 Results

Exhibit 99.1 ? ? ? ? FOR IMMEDIATE RELEASE ? Alimera Sciences Reports First Quarter 2022 Results ? ? Consolidated Net Revenue of $11.9 Million Up 6% vs. First Quarter of 2021 ? U.S. Net Revenue Increased 23% vs. First Quarter of 2021 ? U.S. End User Demand Up 25% vs. First Quarter of 2021 ? ? ATLANTA, May 9, 2022 - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company wh

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission

List of subsidiaries of the Registrant (including jurisdiction of organization and names under which subsidiaries do business)

Exhibit 21.1 Alimera Sciences, Inc. List of Subsidiaries ? ? Name of Wholly-Owned Subsidiary Jurisdiction of Organization Name under which the subsidiary conducts business Alimera Sciences Limited United Kingdom Alimera Sciences Limited Alimera Sciences B.V. The Netherlands Alimera Sciences B.V. Alimera Sciences Opthamologie GmbH Germany Alimera Sciences Opthamologie GmbH Alimera Sciences Europe L

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34

Description of Securities (filed as Exhibit 4.2 to the Registrant’s Form 10-K, as filed March 23, 2022, and incorporated herein by reference)

Exhibit 4.2 DESCRIPTION OF SECURITIES ? Unless the context otherwise requires, throughout this exhibit, the words ?we,? ?us,? or ?our? refer to Alimera Sciences, Inc. and its subsidiaries (as applicable). ? Common Stock ? We currently have authorized 150,000,000 shares of common stock, par value $0.01 per share. As of March 1, 2022, there were 6,992,654 shares of our common stock issued and outsta

As filed with the Securities and Exchange Commission on March 23, 2022

As filed with the Securities and Exchange Commission on March 23, 2022 Registration No.

Filing Fee Table

Exhibit 107.1 Calculation of Filing Fee Tables ? FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ? ALIMERA SCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) ? Table 1: Newly Registered Securities ? ? ? Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amou

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 22, 2022 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissio

Alimera Sciences Reports Fourth Quarter and FY 2021 Results

Exhibit 99.1 ? ? ? ? ? ? Alimera Sciences Reports Fourth Quarter and FY 2021 Results ? Fourth Quarter Highlights: ? Consolidated Net Revenue of $14 Million Up 15% vs. Third Quarter of 2021; Up 1% vs. Fourth Quarter of 2020 ? Full Year 2021 Highlights: ? Consolidated Net Revenue of $59 Million Up 16% vs 2020 ? Consolidated Net Product Revenue of $48 Million ? U.S. Net Revenue Increased 8% vs. 2020

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2022 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissio

ALIM / Alimera Sciences Inc / HIRSCHMAN ORIN Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment No. 3 Under the Securities Exchange Act of 1934 Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259103 (CUSIP Number) February 2, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

 Alimera Sciences Welcomes Ophthalmic Strategic Consultant Erin Parsons to Its Board of Directors

Exhibit 99.1 ? ? ? Alimera Sciences Welcomes Ophthalmic Strategic Consultant Erin Parsons to Its Board of Directors ? ATLANTA (December 1, 2021) ? Alimera Sciences, Inc. (Nasdaq: ALIM) (?Alimera?), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 30, 2021 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 o TRANSITION REPO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe

Change in Control Severance Agreement between Alimera Sciences, Inc., and Philip J. Ashman, Ph.D. as of July 16, 2021 (filed as Exhibit 10.7.H to the Registrant’s Quarterly Report on Form 10-Q, as filed November 5, 2021 and incorporated herein by reference)

Exhibit 10.7H CHANGE IN CONTROL SEVERANCE AGREEMENT BETWEEN PHILIP J. ASHMAN, PH.D. AND ALIMERA SCIENCES, INC. ? This Change in Control Severance Agreement (this ?Agreement?) is entered into between Alimera Sciences, Inc., a Delaware corporation (together with its subsidiaries, the ?Company?), and Philip J. Ashman, Ph.D. (?Executive?), as of July 16, 2021 (the ?Effective Date?). ? RECITALS: ? WHER

UK Sub-Plan to the Alimera Sciences, Inc. 2019 Omnibus Incentive Plan (filed as Exhibit 99.5 to the Registrant’s Registration Statement on Form S-8, as filed on October 29, 2021 and incorporated herein by reference)

Exhibit 99.5 Neither this document, nor any stock option agreement connected with it, is an approved prospectus for the purposes of section 85(1) of the Financial Services and Markets Act 2000 (?FSMA?) and no offer of transferable securities to the public (for the purposes of section 102B of FSMA) is being made in connection with the UK Sub-Plan to the Alimera Sciences, Inc. 2019 Omnibus Incentive

As filed with the Securities and Exchange Commission on October 29, 2021

As filed with the Securities and Exchange Commission on October 29, 2021 Registration No.

Form of UK Sub-Plan Stock Option Agreement (filed as Exhibit 99.6 to the Registrant’s Registration Statement on Form S-8, as filed on October 29, 2021 and incorporated herein by reference)

Exhibit 99.6 UK SUB-PLAN TO THE ALIMERA SCIENCES, INC. 2019 OMNIBUS INCENTIVE PLAN STOCK OPTION AGREEMENT ? THIS STOCK OPTION AGREEMENT (the ?Agreement?) is made and entered into as of the date set forth on Schedule I (?Schedule I?) attached hereto (the ?Date of Grant?) by and between Alimera Sciences, Inc., a Delaware corporation (the ?Company?), and the employee named on Schedule I (the ?Partici

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 28, 2021 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission

Alimera Sciences Announces Third Quarter 2021 Financial Results

Exhibit 99.1 ? ? ? FOR IMMEDIATE RELEASE ? Alimera Sciences Announces Third Quarter 2021 Financial Results ? ? Consolidated Net Revenue of $12.2 Million Down 2% vs. Third Quarter of 2020 and Up 14% vs. Second Quarter of 2021 ? U.S. End User Demand up 15% vs. Third Quarter of 2020 and Second Quarter of 2021 ? ATLANTA, October 28, 2021 - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global phar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 o TRANSITION REPORT PU

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00

Alimera Sciences Announces Second Quarter 2021 Financial Results

Exhibit 99.1 ? ? ? ? ? FOR IMMEDIATE RELEASE Alimera Sciences Announces Second Quarter 2021 Financial Results ? ? Consolidated Net Revenue of $21.7 Million up 117% vs. Second Quarter of 2020 ? Consolidated Net Product Revenue of $10.7 Million up 7% vs. Second Quarter of 2020 ? Net Income of $7.6 Million vs. Net Loss of $2.5 Million in Second Quarter of 2020 ? End User Demand up 16% on a Same Count

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2021 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission

Alimera Sciences, Inc. 2019 Omnibus Incentive Plan, as amended pursuant to stockholder approval on June 15, 2021 (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, as filed on June 16, 2021, and incorporated herein by reference)

Exhibit 10.1 ? ALIMERA SCIENCES, INC. ? 2019 OMNIBUS INCENTIVE PLAN ? As Amended Pursuant to Stockholder Approval on June 15, 2021 ? ? ARTICLE I ? PURPOSE ? Alimera Sciences, Inc. (the ?Company?) has established the Alimera Sciences, Inc. 2019 Omnibus Incentive Plan (the ?Plan?) to attract, retain and motivate directors, officers, employees and consultants of the Company and its Subsidiaries who a

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2021 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Second Amendment to Loan and Security Agreement dated as of March 30, 2021, by and among Alimera Sciences, Inc., SLR Investment Corp. (f/k/a Solar Capital Ltd.), as Collateral Agent, and the parties signatory thereto as Lenders, including SLR in its capacity as a Lender (filed as Exhibit 10.14.F to the Registrant’s Quarterly Report on Form 10-Q, as filed May 7, 2021, and incorporated herein by reference)

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) April 16, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definitive Proxy

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definitive Pro

Alimera Sciences Announces First Quarter 2021 Financial Results

Exhibit 99.1 ? ? ? ? ? FOR IMMEDIATE RELEASE Alimera Sciences Announces First Quarter 2021 Financial Results ? ? ATLANTA, April 28, 2021 - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announced financial results for th

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 28, 2021 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission F

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 12, 2021 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission F

Warrant Subscription Agreement by and between Alimera Sciences, Inc. and Ocumension Therapeutics, dated as of April 14, 2021 (filed as Exhibit 10.3 to the Registrant’s Current Report on Form 8-K as filed on April 14, 2021 and incorporated herein by reference)

Exhibit 10.3 Dated 14 April 2021 ? ? ? ? ? OCUMENSION THERAPEUTICS (as Issuer) ? ? and ? ? ALIMERA SCIENCES, INC. (as Subscriber) ? ? ? ? ? WARRANT SUBSCRIPTION AGREEMENT ? ? ? ? ? THIS AGREEMENT is dated 14 April 2021 ? BETWEEN: ? (1)OCUMENSION THERAPEUTICS (??????), a company incorporated under the laws of the Cayman Islands with limited liability having its registered office at P.O. Box 31119 G

 Alimera Sciences receives $20 million from Ocumension Therapeutics

Exhibit 99.1    FOR IMMEDIATE RELEASE   Alimera Sciences receives $20 million from Ocumension Therapeutics  · Alimera grants exclusive license to Ocumension for a $10 million upfront payment and up to $89 million in additional sales-based milestone payments · Ocumension makes a $10 million equity investment in Alimera  ATLANTA, April 14, 2021 – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera

Exclusive License Agreement by and between and Ocumension (Hong Kong) Limited, dated as of April 14, 2021 (filed as Exhibit 10.4 to the Registrant’s Current Report on Form 8-K as filed on April 14, 2021 and incorporated herein by reference)

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).

Voting and Investor Rights Agreement by and between Alimera Sciences, Inc. and Ocumension Therapeutics, dated as of April 14, 2021 (filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K as filed on April 14, 2021 and incorporated herein by reference)

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).

Share Purchase Agreement by and between Ocumension Therapeutics and Alimera Sciences, Inc., dated as of April 14, 2021 (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K as filed on April 14, 2021 and incorporated herein by reference)

Exhibit 10.1 Execution Version SHARE PURCHASE AGREEMENT THIS SHARE PURCHASE AGREEMENT (this ?Agreement?) is made as of April 14, 2021, by and between Ocumension Therapeutics, incorporated in the Cayman Islands with limited liability (?Investor?), and Alimera Sciences, Inc., a Delaware corporation (the ?Company?). WHEREAS, pursuant to the terms and subject to the conditions set forth in this Agreem

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2021 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission F

Description of Securities

Exhibit 4.3 DESCRIPTION OF SECURITIES ? Unless the context otherwise requires, throughout this exhibit, the words ?we,? ?us,? or ?our? refer to Alimera Sciences, Inc. and its subsidiaries (as applicable). ? Common Stock ? We currently have authorized 150,000,000 shares of common stock, par value $0.01 per share. As of March 1, 2021, there were 5,753,434 shares of the registrant?s common stock issu

List of subsidiaries of the Registrant (including jurisdiction of organization and names under which subsidiaries do business)

Exhibit 21.1 Alimera Sciences, Inc. List of Subsidiaries ? ? Name of Wholly-Owned Subsidiary Jurisdiction of Organization Name under which the subsidiary conducts business Alimera Sciences Limited United Kingdom Alimera Sciences Limited Alimera Sciences B.V. The Netherlands Alimera Sciences B.V. Alimera Sciences Opthamologie GmbH Germany Alimera Sciences Opthamologie GmbH Alimera Sciences Europe L

Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34

Alimera Sciences Reports Fourth Quarter and 2020 Results

Exhibit 99.1 ? ? ? ? ? ? ? FOR IMMEDIATE RELEASE ? Alimera Sciences Reports Fourth Quarter and 2020 Results ? Fourth Quarter Highlights: ? Consolidated Net Revenue of $13.8 Million Up 10% vs. Third Quarter of 2020 ? Consolidated Net Revenue Down 20% vs. Fourth Quarter of 2019 Due to COVID-19 Impact ? Net Loss of $(1.0) Million vs. Net Income of $0.5 Million in Fourth Quarter of 2019 ? $1.1 Million

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2021 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissio

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 11, 2021 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissio